# A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

> clinical trial · VERIFIED · 2026-06-15

Status: RECRUITING · Sponsor: Regeneron Pharmaceuticals · Condition: Monoclonal Gammopathy of Undetermined Significance (MGUS)

- Company: Regeneron Pharmaceuticals
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06140524

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.